Open AccessKRAS mutant lung cancer: progress thus far on an elusive therapeutic target
Author(s) -
Bhattacharya Saveri,
Socinski Mark A.,
Burns Timothy F.
Publication year - 2015
Publication title -
clinical and translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2001-1326
DOI - 10.1186/s40169-015-0075-0
Subject(s) - kras , lung cancer , medicine , mapk/erk pathway , mutant , cancer research , mutation , targeted therapy , cancer , oncology , mek inhibitor , biology , signal transduction , colorectal cancer , genetics , gene
The KRAS mutation remains the most common driver mutation in patients with non‐small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS‐RAF‐MEK‐ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.